Literature DB >> 35940876

Peroxisome injury in multiple sclerosis: protective effects of 4-phenylbutyrate in CNS-associated macrophages.

Andrej Roczkowsky1, Matthew A L Doan2, Brittyne Hlavay1, Manmeet K Mamik1, William G Branton1, Brienne A McKenzie3, Leina B Saito3, Laura Schmitt4, Gary Eitzen5, Francesca Di Cara6, Melinda Wuest7, Frank Wuest7, Richard Rachubinski5, Christopher Power8,3,2.   

Abstract

OBJECTIVES: Multiple sclerosis (MS) is a progressive and inflammatory demyelinating disease of the central nervous system (CNS). Peroxisomes perform critical functions that contribute to CNS homeostasis. We investigated peroxisome injury and mitigating effects of peroxisome-restorative therapy on inflammatory demyelination in models of MS.
METHODS: Human autopsied CNS tissues (male and female), human cell cultures and cuprizone-mediated demyelination mice (female) were examined by RT-PCR, western blotting and immunolabeling. The therapeutic peroxisome proliferator, 4-phenylbutyrate (4-PBA) was investigated in vitro and in vivo.
RESULTS: White matter from MS patients showed reduced peroxisomal transcript and protein levels, including PMP70, compared to non-MS controls. Cultured human neural cells revealed that human microglia contained abundant peroxisomal proteins. TNF-α-exposed microglia displayed reduced immunolabeling of peroxisomal proteins, PMP70 and PEX11β, which was prevented with 4-PBA. In human myeloid cells exposed to TNF-α or nigericin, suppression of PEX11β and catalase protein levels were observed to be dependent on NLRP3 expression. Hindbrains from cuprizone-exposed mice showed reduced Abcd1, Cat, and Pex5l transcript levels, with concurrent increased Nlrp3 and Il1b transcript levels, which was abrogated by 4-PBA. In the central corpus callosum, Iba-1 in CNS-associated macrophages (CAMs) and peroxisomal thiolase immunostaining after cuprizone exposure was increased by 4-PBA. 4-PBA prevented decreased myelin basic protein and neurofilament heavy chain immunoreactivity caused by cuprizone exposure. Cuprizone-induced neurobehavioral deficits were improved by 4-PBA treatment.
CONCLUSIONS: Peroxisome injury in CAMs, contributed to neuroinflammation and demyelination that was prevented by 4-PBA treatment. A peroxisome-targeted therapy might be valuable for treating inflammatory demyelination and neurodegeneration in MS.Significance statement:Multiple sclerosis (MS) is a common and disabling disorder of the CNS with no curative therapies for its progressive form. The present studies implicate peroxisome impairment in CNS-associated macrophages (CAMs), which include resident microglia and blood-derived macrophages, as an important contributor to inflammatory demyelination and neuroaxonal injury in MS. We also show that the inflammasome molecule NLRP3 is associated with peroxisome injury in vitro and in vivo, especially in CAMs. Treatment with the peroxisome proliferator 4-phenylbutyrate exerted protective effects with improved molecular, morphological and neurobehavioral outcomes that were associated with a neuroprotective CAM phenotype. These findings offer novel insights into the contribution of peroxisome injury in MS together with preclinical testing of a rational therapy for MS.
Copyright © 2022 the authors.

Entities:  

Year:  2022        PMID: 35940876      PMCID: PMC9480879          DOI: 10.1523/JNEUROSCI.0312-22.2022

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.709


  57 in total

1.  LACC1 Regulates TNF and IL-17 in Mouse Models of Arthritis and Inflammation.

Authors:  Cara Skon-Hegg; Juan Zhang; Xiumin Wu; Meredith Sagolla; Naruhisa Ota; Arthur Wuster; Jennifer Tom; Emma Doran; Nandhini Ramamoorthi; Patrick Caplazi; John Monroe; Wyne P Lee; Timothy W Behrens
Journal:  J Immunol       Date:  2018-12-03       Impact factor: 5.422

2.  Peroxisomal proliferation protects from beta-amyloid neurodegeneration.

Authors:  Manuel J Santos; Rodrigo A Quintanilla; Andrés Toro; Rodrigo Grandy; Margarita C Dinamarca; Juan A Godoy; Nibaldo C Inestrosa
Journal:  J Biol Chem       Date:  2005-10-03       Impact factor: 5.157

Review 3.  Immunomodulation of microglia by docosahexaenoic acid and eicosapentaenoic acid.

Authors:  Erik Hjorth; Yvonne Freund-Levi
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2012-03       Impact factor: 4.294

4.  Impaired neurogenesis and associated gliosis in mouse brain with PEX13 deficiency.

Authors:  Rani Sadia Rahim; James A St John; Denis I Crane; Adrian C B Meedeniya
Journal:  Mol Cell Neurosci       Date:  2017-12-02       Impact factor: 4.314

Review 5.  Multiple sclerosis.

Authors:  Massimo Filippi; Amit Bar-Or; Fredrik Piehl; Paolo Preziosa; Alessandra Solari; Sandra Vukusic; Maria A Rocca
Journal:  Nat Rev Dis Primers       Date:  2018-11-08       Impact factor: 52.329

6.  High content screening for non-classical peroxisome proliferators.

Authors:  Jonathan Z Sexton; Qingping He; Lawrence J Forsberg; Jay E Brenman
Journal:  Int J High Throughput Screen       Date:  2010-07

7.  HIV-1 Viral Protein R Activates NLRP3 Inflammasome in Microglia: implications for HIV-1 Associated Neuroinflammation.

Authors:  Manmeet K Mamik; Elizabeth Hui; William G Branton; Brienne A McKenzie; Jesse Chisholm; Eric A Cohen; Christopher Power
Journal:  J Neuroimmune Pharmacol       Date:  2016-10-10       Impact factor: 4.147

8.  Mutations in the 70K peroxisomal membrane protein gene in Zellweger syndrome.

Authors:  J Gärtner; H Moser; D Valle
Journal:  Nat Genet       Date:  1992-04       Impact factor: 38.330

9.  Rapid inflammasome activation in microglia contributes to brain disease in HIV/AIDS.

Authors:  John G Walsh; Stacey N Reinke; Manmeet K Mamik; Brienne A McKenzie; Ferdinand Maingat; William G Branton; David I Broadhurst; Christopher Power
Journal:  Retrovirology       Date:  2014-05-13       Impact factor: 4.602

10.  NLRP3 inflammasome as prognostic factor and therapeutic target in primary progressive multiple sclerosis patients.

Authors:  Sunny Malhotra; Carme Costa; Herena Eixarch; Christian W Keller; Lukas Amman; Helios Martínez-Banaclocha; Luciana Midaglia; Eduard Sarró; Isabel Machín-Díaz; Luisa M Villar; Juan Carlos Triviño; Begoña Oliver-Martos; Laura Navarro Parladé; Laura Calvo-Barreiro; Fuencisla Matesanz; Koen Vandenbroeck; Elena Urcelay; María-Luisa Martínez-Ginés; Amalia Tejeda-Velarde; Nicolás Fissolo; Joaquín Castilló; Alex Sanchez; Avril A B Robertson; Diego Clemente; Marco Prinz; Pablo Pelegrin; Jan D Lünemann; Carmen Espejo; Xavier Montalban; Manuel Comabella
Journal:  Brain       Date:  2020-05-01       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.